Linus Biotechnology
LinusBio is a pioneering platform company developing precision exposome biomarkers to enable earlier diagnoses, enhance patient monitoring, and accelerate drug development, especially in complex conditions like autism spectrum disorder, ALS, and other neurological and complex diseases.
Industries
Nr. of Employees
small (1-50)
Linus Biotechnology
675 US-1, North Brunswick Township, NJ 08902
Products
Hair-based biochemical screening test for autism (diagnostic aid)
A laboratory-performed, non-genetic biochemical screening intended to help health care providers rule out autism in children (intended age range reported as 1–48 months in public materials). The assay analyzes a single hair strand to map time-resolved biochemical patterns and applies an algorithm to assess likelihood of ASD; results are provided by a CLIA-certified laboratory and the test must be ordered by a licensed provider (Rx-only as reported).
Hair-based biochemical screening test for autism (diagnostic aid)
A laboratory-performed, non-genetic biochemical screening intended to help health care providers rule out autism in children (intended age range reported as 1–48 months in public materials). The assay analyzes a single hair strand to map time-resolved biochemical patterns and applies an algorithm to assess likelihood of ASD; results are provided by a CLIA-certified laboratory and the test must be ordered by a licensed provider (Rx-only as reported).
Services
Provision of temporal exposomic sequencing and analytical services to support biomarker discovery, pathway characterization, and use as molecular endpoints in clinical trials.
Laboratory testing services performed in a CLIA-certified facility using hair-derived exposomic assays to generate clinically reportable results for provider-ordered diagnostic aids.
Structured collaborations with advocacy groups, care platforms, industry partners, and academic investigators to expand access, research use, and clinical validation of exposomic biomarkers.
Medical information request and clinician support services to respond to healthcare professional inquiries about tests, data, and clinical usage.
Provision of temporal exposomic sequencing and analytical services to support biomarker discovery, pathway characterization, and use as molecular endpoints in clinical trials.
Laboratory testing services performed in a CLIA-certified facility using hair-derived exposomic assays to generate clinically reportable results for provider-ordered diagnostic aids.
Structured collaborations with advocacy groups, care platforms, industry partners, and academic investigators to expand access, research use, and clinical validation of exposomic biomarkers.
Medical information request and clinician support services to respond to healthcare professional inquiries about tests, data, and clinical usage.
Expertise Areas
- Precision exposomics
- Biomarker discovery and validation
- Mass spectrometry-based analytics
- Laboratory automation and scale-up
Key Technologies
- Temporal exposome sequencing
- Hair-based temporal sampling
- Laser-based sample extraction
- High-resolution mass spectrometry
News & Updates
Partnership integrates ClearStrand-ASD™ with full-spectrum care to streamline autism diagnosis and early intervention.
Partnership to utilize ClearStrand-ASD to support earlier autism diagnosis and intervention.
Collaboration to support autism biomarker research and facilitate early identification and intervention.
Recognition for innovation in precision exposome sequencing technology and its impact on health conditions.
Introduction of a biochemical test that identifies a molecular signature predictive of autism in a strand of hair, enabling early and non-invasive screening.
Award for developing a novel precision exposome sequencing platform for complex diseases, including autism.
Partnership integrates ClearStrand-ASD™ with full-spectrum care to streamline autism diagnosis and early intervention.
Partnership to utilize ClearStrand-ASD to support earlier autism diagnosis and intervention.
Collaboration to support autism biomarker research and facilitate early identification and intervention.
Recognition for innovation in precision exposome sequencing technology and its impact on health conditions.
Introduction of a biochemical test that identifies a molecular signature predictive of autism in a strand of hair, enabling early and non-invasive screening.
Award for developing a novel precision exposome sequencing platform for complex diseases, including autism.